ResearcherChina Pharmaceutical UniversityNo recent work listed

Yungen Xu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-6586-8482; OpenAlex author ID A5090079560. Sources: OpenAlex.

Their work

Papers: 4 (first author 0, last author 2)
Trials: 0
Grants: 0
Labs led: 1
Collaborators: 9

Papers, trials and grants by year

2021: 1 paper · 2022: 2 papers · 2023: 1 paper

Papers 4

Design, synthesis and biological evaluation of novel DCLK1 inhibitor containing purine skeleton for the treatment of pancreatic cancer. Last author DOI 10.1016/j.ejmech.2023.115846 ↗
Design, synthesis and mechanism studies of novel dual PARP1/BRD4 inhibitors against pancreatic cancer. Co-author DOI 10.1016/j.ejmech.2022.114116 ↗
FDI-6 and olaparib synergistically inhibit the growth of pancreatic cancer by repressing BUB1, BRCA1 and CDC25A signaling pathways. Co-author DOI 10.1016/j.phrs.2021.106040 ↗
Discovery of Potent and Novel Dual PARP/BRD4 Inhibitors for Efficient Treatment of Pancreatic Cancer. Last author DOI 10.1021/acs.jmedchem.1c01535 ↗

Closest collaborators

The 9 strongest of 9 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Shihui Huang · 3 shared papers, 2021–2022 · strength 0.44
Shiqi Wu · 3 shared papers, 2021–2022 · strength 0.44
Qin Sun · 2 shared papers, 2021–2022 · strength 0.27
- Paper Design, synthesis and mechanism studies of novel dual PARP1/BRD4 inhibitors against pancreatic cancer. DOI 10.1016/j.ejmech.2022.114116 ↗
- Paper Discovery of Potent and Novel Dual PARP/BRD4 Inhibitors for Efficient Treatment of Pancreatic Cancer. DOI 10.1021/acs.jmedchem.1c01535 ↗
Shuping Wang · 1 shared paper, 2022 · strength 0.17
- Paper FDI-6 and olaparib synergistically inhibit the growth of pancreatic cancer by repressing BUB1, BRCA1 and CDC25A signali… DOI 10.1016/j.phrs.2021.106040 ↗
Wenze Wang · 1 shared paper, 2023 · strength 0.17
- Paper Design, synthesis and biological evaluation of novel DCLK1 inhibitor containing purine skeleton for the treatment of pa… DOI 10.1016/j.ejmech.2023.115846 ↗
Yuepeng Chen · 1 shared paper, 2023 · strength 0.17
- Paper Design, synthesis and biological evaluation of novel DCLK1 inhibitor containing purine skeleton for the treatment of pa… DOI 10.1016/j.ejmech.2023.115846 ↗
Shuping Wang · 1 shared paper, 2022 · strength 0.15
- Paper Design, synthesis and mechanism studies of novel dual PARP1/BRD4 inhibitors against pancreatic cancer. DOI 10.1016/j.ejmech.2022.114116 ↗
Yu Li · 1 shared paper, 2021 · strength 0.12
- Paper Discovery of Potent and Novel Dual PARP/BRD4 Inhibitors for Efficient Treatment of Pancreatic Cancer. DOI 10.1021/acs.jmedchem.1c01535 ↗
Shu-Ping Wang · 1 shared paper, 2021 · strength 0.12
- Paper Discovery of Potent and Novel Dual PARP/BRD4 Inhibitors for Efficient Treatment of Pancreatic Cancer. DOI 10.1021/acs.jmedchem.1c01535 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.